304 North Cardinal St.
Dorchester Center, MA 02124
Product Name: Caboxen
Brand Name: Cabometyx, Cometriq
Manufacturer: Everest Pharmaceutical.
Generic Name: Cabozantinib
Strength: 20mg, 80mg
Volume: 90 Tablets
Target: Thyroid Cancer
Contact: WhatsApp & WeChat +8801304498958
Caboxen-20/80mg(Cabozantinib) is a type of non-specific tyrosine kinase inhibitor medication that was first approved in 2012 for treating metastatic medullary thyroid cancer. It was developed by Exelixis Inc. In 2016, a capsule form of this medication called Cabometyx was approved for advanced renal cell carcinoma. Additionally, in 2019, Cabometyx was approved for treating hepatocellular carcinoma in patients who were previously treated. Cabozantinib works by inhibiting tyrosine kinases c-Met and VEGFR2, as well as AXL and RET. Cometriq was approved by the US Food and Drug Administration (FDA) to treat medullary thyroid cancer in 2012, while the European Union approved the capsule form in 2014. Furthermore, in 2016, the FDA approved the tablet formulation of Cabozantinib as a second-line treatment for kidney cancer. (1)
Caboxen-20/80mg(Cabozantinib) is indicated for the treatment of progressive, metastatic medullary thyroid cancer. It is also indicated for the treatment of advanced renal cell carcinoma and for hepatocellular carcinoma in patients previously treated with sorafenib.
Caboxen also used for associate treatment of
Caboxen-20/80mg(Cabozantinib) is a type of cancer drug known as a multi-targeted tyrosine kinase inhibitor (TKI). It works by blocking the activity of enzymes known as tyrosine kinases, which are involved in cell growth and division. By doing so, TKIs can help to slow or stop the growth of cancer cells. Cabozantinib has been shown to inhibit various tyrosine kinases, including VEGFR-1, -2, and -3, MET, AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT-3, and TIE-2. These enzymes are involved in several cellular processes such as angiogenesis (the formation of new blood vessels), tumor growth and metastasis, cell survival, and immune function.
Cabozantinib helps in reducing tumor blood supply, blocking tumor growth and metastasis, promoting tumor cell death, and modulating the immune response. Although the exact mechanism of action of cabozantinib in different types of cancer is still being investigated, it is believed that the broad-spectrum anti-tumor activity of the drug is due to its ability to inhibit multiple tyrosine kinases. (3)
Caboxen-20/80mg(Cabozantinib) is a medication that is used to treat various conditions, including stomach upset. It should be taken once daily, either before or after a meal. The dosage can be reduced to 40 or 20 mg if required. The drug is rapidly absorbed and reaches its maximum plasma concentration within 3 to 4 hours. It binds strongly to plasma proteins, with a maximum concentration of 99.7%. The liver extensively metabolizes the drug, and major metabolites are excreted in feces, with a smaller amount in urine. The half-life of the drug is approximately 100 hours.
The side effects of Caboxen-20/80mg(Cabozantinib) can vary in severity and frequency from person to person. The most common side effects are:
Less common side effects can include:
It is important to note that some of the side effects of cabozantinib can be serious. If you experience any of the following side effects, you should contact your doctor immediately:
Cabozantinib is a cancer treatment that has demonstrated promising results in prolonging the lives of patients with various types of cancer.
Ipsen is a global biopharmaceutical company that focuses on innovation and specialty care. They specialize in developing and commercializing medicines in the fields of Oncology, Neuroscience, and Rare Diseases. Ipsen is committed to investing more than 20% of their sales in research and development, and has played a crucial role in the development and commercialization of cabozantinib. With a strong background in oncology and a deep understanding of the needs of cancer patients, Ipsen is dedicated to providing access to cabozantinib for patients all over the world.
Cabozantinib-s-malate is a salt form of cabozantinib. Salts of drugs are often more soluble than the parent drug, which can make them easier to formulate and administer. Cabozantinib-s-malate is the active ingredient in the drug Cabometyx, which is used to treat a variety of cancers, including renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer.
Anti-cancer medicines are very expensive almost 90% of cancer patients can not afford these medicines. Some of them get access to these medicines by their insurance but insurance cost is also high for these medicines. That’s why patients do not get proper treatment. Meds for Cancer make these medicines affordable for those patients who cannot buy these expensive medicines or they are not covered by health insurance. We provide the best quality medicine at the best price in every corner of the world. To know the Price of this medicine get in touch with us. Contacting us is very easy you can use this number +8801304498958 to contact us through WhatsApp and WeChat.
The news hit Mark like a freight train. Stage 4 renal cell carcinoma. Advanced kidney cancer. His world tilted on its axis, casting uncertainty where hope once bloomed. Yet, amidst the storm, a beacon emerged: cabozantinib, a targeted therapy offering a lifeline.
At the renowned Genitourinary Cancers Symposium, Mark’s oncologist spoke of cabozantinib’s potential, particularly for patients with metastatic RCC, like him. Studies showcased how cabozantinib 60mg, compared to its rivals, yielded remarkable results. Patients receiving cabozantinib experienced significant tumor shrinkage, some achieving complete responses, meaning the cancer vanished altogether. Overall survival (OS), the ultimate measure of success, climbed, offering precious time and renewed hope.
Mark embarked on his cabozantinib journey with apprehension and a resolute spirit. The Cancer Center became his second home, where the hum of machines and the warmth of dedicated nurses became a familiar lullaby. Side effects, while present, were manageable, a small price for the glimmers of progress visible on scans.
Months turned into years, and Mark defied the odds. Tumors shrunk, stabilized, and in some cases, simply disappeared. He rediscovered the joys of daily life, savoring walks with his family, the laughter of grandchildren, and the quiet intimacy of shared meals. Cabozantinib, once a whisper of hope, became a resounding victory chant.
Mark’s story is not unique. It echoes in the lives of countless others who, armed with cabozantinib, face advanced kidney cancer with courage and newfound optimism. It’s a testament to the relentless pursuit of innovation in cancer treatment, where targeted therapies like cabozantinib rewrite the narrative, turning despair into milestones of resilience.
So, when the shadows of advanced kidney cancer loom, remember Mark, and remember the power of cabozantinib (Cabometyx). It’s a story still being written, one chapter of hope at a time.